---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-039341"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:00:41.540927+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cellectar reports FY2023 net loss $38M; plans iopofosine NDA submission H2 2024

## Summary
- Net loss $38.0M ($3.11 per share) vs $28.6M ($4.05) in prior year.
- Cash $9.6M at Dec 31, 2023; plus $44.1M from Jan 2024 warrant exercise funds into Q4 2024.
- CLOVER WaM study met primary endpoint: MRR 61%, ORR 75.6%, 7.3% CR in refractory WM.
- R&D expense $28.2M, up 47% YoY, driven by manufacturing for trials and commercial readiness.
- Positive topline data announced; NDA submission planned H2 2024 with request for accelerated approval.

## SEC filing metadata
- accession: 0001104659-24-039341
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924039341/0001104659-24-039341-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924039341/tm249908d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-039341
- JSON: https://secwatch.observer/filing/0001104659-24-039341.json
- Plain text: https://secwatch.observer/filing/0001104659-24-039341.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported financial results for year ended December 31, 2023.
  - Period: year ended December 31, 2023
  - Result: reported results
  source text: Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465924039341/0001104659-24-039341-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.